This Startup Wants To Catch Cancer In Its Early Days

A race is on among Silicon Valley startups to catch cancers before they turn deadly. Victory will come for the winners in a drop of blood — a sample serving as a long-sought “liquid biopsy” for cancer.

One contestant is Freenome of South San Francisco, California, which announced on Wednesday that it has raised $65 million to test their experimental liquid biopsy and move it closer to commercialization.

CEO Gabriel Otte says Freenome is most interested in preventing cancer in the first place. “We see these screenings as a catch-all, first line of defense you might be able to take, as easy as doing a yearly physical,” he told BuzzFeed News.


Next Page

Be the first to comment

Leave a Reply

Your email address will not be published.